



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

**Effective Date: 10/12/2023**

**Spevigo® (spesolimab-sbvo)**

**HCPCS: J1747**

**Policy:**

*Requests must be supported by submission of chart notes and patient specific documentation.*

- A. Coverage of the requested drug is provided when all the following are met:
  - a. FDA approved age
  - b. Patient has a history of generalized pustular psoriasis (GPP) as defined by the European Rare and Severe Psoriasis Expert Network
  - c. Patient is experiencing a GPP flare of moderate-to-severe intensity defined by all of the following:
    - i. A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score  $\geq 3$
    - ii. New or worsening pustules
    - iii. GPPGA pustulation sub-score  $\geq 2$
    - iv.  $\geq 5\%$  of body surface area (BSA) with erythema and the presence of pustules
  - d. Trial and failure, contraindication, or intolerance to one of the following systemic therapies: acitretin, cyclosporine, methotrexate, infliximab
  - e. Not to be used in combination with other biologics or targeted DMARDs
  - f. Trial and failure, contraindication, OR intolerance to the preferred drugs as listed in BCBSM/BCN's utilization management medical drug list.
  
- B. Quantity Limitations, Authorization Period and Renewal Criteria
  - a. Quantity Limit: Align with FDA recommended dosing
  - b. Initial Authorization Period: 12 weeks
  - c. Renewal Criteria: Not applicable as no further authorization will be provided.

\*\*\*Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

## Background Information:

- Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening neutrophilic skin disease characterized by flares consisting of widespread eruptions of painful, sterile pustules. Patients with acute GPP may appear systemically ill and require hospital admission for adequate supportive care, and flares can be so disruptive to the system that they can trigger sepsis, cardiovascular complications, and renal failure. It is estimated that 1 out of every 10,000 people has GPP, and because it is so rare the condition is often under- or mis-diagnosed. Mortality ranges from 2% to 16% with deaths often attributed to septic shock and cardiorespiratory failure. Clinical course of GPP varies and can be relapsing with recurrent flares or persistent with intermittent flares. Flare frequency varies among patients and may be spontaneous or triggered by stress, infection, medication, or pregnancy.
- The European Rare and Severe Psoriasis Expert Network (ERASPEN) consensus statement on phenotypes of pustular psoriasis (2017) define GPP as macroscopically visible primary sterile pustules occurring on non-acral skin and not within psoriasis plaques. GPP may occur with or without systemic inflammation and with or without psoriasis vulgaris and should only be diagnosed when the condition has relapsed at least once or when it persists for more than 3 months. The expert group advises against counting pustules to measure GPP intensity as the spectrum can vary from discrete to confluent forms and notes there is an unmet need for development of a clinically validated standard to measure GPP severity.
- The goals of treatment of GPP are to improve skin manifestations, alleviate systemic symptoms, and minimize the risk for life-threatening systemic complications. There are no standard US or international guidelines for the treatment of GPP as high-quality data on the efficacy of treatments is lacking. Treatment options include systemic therapies, topicals, and phototherapy. Phototherapy has a delayed onset of action, and due to the widespread nature of GPP topicals may not be practical; therefore, these therapies are typically reserved as adjuncts to systemic therapy for the treatment of GPP.
- Japanese guidelines for the treatment of GPP (2018) and the National Psoriasis Foundation (NPF) Medical Board (2012) recommend an oral retinoid (e.g. acitretin), cyclosporine, methotrexate, and various biologics as potential systemic treatments for GPP. In the United States, these therapies are used off-label to treat GPP flares. The choice of systemic agent is based on disease severity and may differ between those with severe acute disease and those with stable disease. It should be noted that demonstration of efficacy with any of these agents is solely based on limited evidence from case reports and small, uncontrolled trials. No randomized controlled trials or other comparative studies have been done comparing treatment methods.
- A retinoid like acitretin is considered a first-line agent for GPP. Improvement (i.e., cessation of new pustule formation, initial improvement in other clinical signs) is typically seen within 7 to 10 days of initiating therapy, and a complete response is noted after 2 to 3 months of treatment. Methotrexate is an alternative, particularly for those intolerant to retinoids, with significant clinical improvement expected within 8 to 12 weeks of treatment. These agents can be continued for long-term maintenance treatment once the flare has resolved; however, due to their slow onset of action they are best suited for patients with less severe disease.
- More severe, acute GPP flares require rapid stabilization and improvement. For these patients, faster-acting drugs such as cyclosporine, infliximab, and interleukin (IL)-17 and IL -23 receptor antagonists are preferred. Cyclosporine and infliximab have a longer history of use compared to the IL-17 and IL-23 biologics, and both therapies are supported by the NPF Medical Board and the Japanese guidelines. Marked improvement is often seen within the first few days of treatment with either of these agents. Some case reports with cyclosporine have demonstrated near-complete remission within 2 weeks, and Japanese guidelines cite the effects of infliximab as apparent within 24-48 hours in many cases and a clear effect often seen after 1 to 3 administrations. Once the flare has resolved, patients can be transitioned to alternative therapies like methotrexate or a retinoid for maintenance or remain on infliximab. For those treated with cyclosporine, however, transitioning to another drug for maintenance is recommended due to side effect concerns with prolonged cyclosporine use.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

- IL-17 inhibitors that have demonstrated benefit in small studies and case reports in GPP flares include secukinumab, ixekizumab and brodalumab. These drugs are approved to treat GPP in Japan and the Japanese guidelines support their use. Ustekinumab, an IL-23 inhibitor, has shown some efficacy in case reports for GPP; however, it is not approved for this indication in Japan and the Japanese guidelines suggest reserving use for those resistant to other treatment modalities. Dosing of interleukin receptor antagonists generally reflects doses recommended for plaque psoriasis; however, the optimal treatment regimen for GPP is unknown.
- In addition to select interleukin receptor antagonists, the tumor necrosis factor (TNF) inhibitors adalimumab and etanercept have demonstrated successful control of GPP in small numbers of patients. These drugs are considered second-line therapies for GPP flares by the NPF Medical Board and the Japanese guidelines. Of note, there are reports of TNF inhibitors inducing pustular psoriasis, including GPP.
- Spevigo (spesolimab-sbvo) is the first and only therapy approved in the United States to treat GPP flares in adults. It is an IL-36 inhibitor and is the first approved drug in this class. Loss-of-function mutations in the IL-36 receptor antagonist gene and other associated genes as well as overexpression of IL-36 cytokines in GPP skin lesions have been found in patients with GPP and support the role of the IL-36 pathway in the disease process.
- In the Phase II, randomized, multicenter, double-blind, placebo-controlled Effisayil-1 trial, adults 18 to 75 years of age who had a history of GPP consistent with the ERASPEN diagnostic criteria and presenting with a GPP flare were randomly assigned in a 2:1 ratio to receive a single IV dose of Spevigo (n=35) or placebo (n=18). Patients were followed through week 12. The primary endpoint was a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 (no visible pustules) at the end of week 1. The key secondary end point was a GPPGA total score of 0 or 1 (clear or almost clear skin) at the end of week 1. Scores range from 0 to 4, with higher scores indicating greater disease severity. Refer to Appendix A for a full description of the GPPGA.
  - Trial participants were required to have a GPP flare of moderate to severe intensity as defined by the following:
    - A GPPGA total score of  $\geq 3$ ,
    - New or worsening pustules,
    - A GPPGA pustulation sub-score of  $\geq 2$ , and
    - $\geq 5\%$  of body-surface area with erythema and the presence of pustules.
  - At the end of week 1, 54% (19 of 35) patients in the Spevigo group met the primary endpoint compared to 6% (1 in 18) in the placebo group ( $p < 0.001$ ). Additionally, 43% (15 of 35) of patients treated with Spevigo showed clear/almost clear skin compared to 11% (2 of 18) in the placebo group ( $p = 0.02$ ).
  - Patients in both groups were eligible to receive a single open-label dose of Spevigo on day 8 if the flare symptoms persisted as defined by a GPPGA total score  $\geq 2$  at the end of week 1, a clinician assessment of GPP severity based on a modified Physician Global Assessment, and a GPPGA pustulation sub-score of  $\geq 2$  at week 1.
  - Both groups were also eligible to receive rescue treatment with a single dose of Spevigo in the case of flare reoccurrence after week 1, which was defined as an increase of  $\geq 2$  points in both the GPPGA total score and the pustulation sub-score after a GPPGA total score of 0 or 1 had been reached. It should be noted that only one rescue dose with Spevigo was allowed in the trial if a patient experienced a reoccurrence of a GPP flare after achieving clinical response to either Spevigo at day 1, placebo at day 1, escape medication, or an

open-label dose of Spevigo at Day 8. Subsequent flares were treated with standard of care therapy per the physician's discretion.

- All patients in the trial were followed through 12 weeks. Effect on pustular and skin clearance was sustained over 12 weeks, with 84.4% who received Spevigo having no visible pustules after the 12 week trial duration, and 81.3% having clear/almost clear skin. Additionally, clearance was accompanied by clinically significant improvements in quality of life and symptoms such as pain and fatigue.
- Spevigo is recommended as a single IV infusion to treat a GPP flare. If flare symptoms persist, an additional dose may be administered one week after the initial dose. There is no literature supporting the continued use of Spevigo as maintenance treatment for the prevention of GPP flares, and longer and larger trials are warranted to determine Spevigo's effect and safety in patients with pustular psoriasis.
- Spevigo fills an unmet need as the only FDA-approved treatment for GPP flares. Spevigo has high-quality evidence supporting its effectiveness for GPP flares; however, the off-label alternatives currently in use for GPP flares can be used for both flares and prevention and are significantly less expensive by comparison. It is worth noting that evidence supporting the efficacy of these off-label therapies is limited and not high-quality, and it is unknown how Spevigo compares to the alternatives currently in use for treating GPP flares or how these alternatives compare to one another.

#### References:

1. Navarini AA, Burden AD, et al. European consensus statement on phenotypes of pustular psoriasis. *J Eur Acad Dermatol Venerol*. 2017 Nov;32(11):1792-1799. doi: 10.1111/jdv.14386.
2. Spevigo [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; September 2022.
3. Manufacturer press release. FDA approves first treatment option for generalized pustular psoriasis flares in adults. September 1, 2022. Accessed on September 6, 2022. Available at: <https://www.boehringer-ingelheim.us/press-release/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults>.
4. Fujita H, Terui T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. *Journal of Dermatology* 2018; 45: 1235-1270.
5. Bachelez H, Choon SE, et al. Trial of Spesolimab for Generalized Pustular Psoriasis. *N Engl J Med* 2021; 385: 2431-40.
6. Robinson A, Van Voorhees, AS, et al. Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* 2012;67:279-88.
7. Kalb RE. Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis. In: UpToDate, Shefner JM (Ed), UpToDate, Waltham, MA. (Accessed September 6, 2022).
8. Kalb RE. Pustular psoriasis: Management. In: UpToDate, Shefner JM (Ed), UpToDate, Waltham, MA. (Accessed September 6, 2022).
9. Krueger J, Puig L, Thaci D. Treatment Options and goals for Patients with Generalized Pustular Psoriasis. *Am J Clin Dermatol* 23 (Suppl 1), 51–64 (2022). <https://doi.org/10.1007/s40257-021-00658-9>.
10. Burden AD, et al. Clinical Disease Measures in Generalized Pustular Psoriasis. *Am J Clin Dermatol* (2022) 23 (Suppl1):@39-s50. <https://doi.org/10.1077/s40257-021-00653-0>.

Policy History												
#	Date	Change Description										
1.3	Effective Date: 10/12/2023	Annual review of criteria performed, no changes were made										
1.2	Effective Date: 10/13/2022	UM medical management system update for BCBS and BCN <table border="1" data-bbox="483 338 1365 548"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>Yes</td> </tr> <tr> <td>BCNA</td> <td>Yes</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	Yes											
BCNA	Yes											
1.1	Effective Date: 10/06/2022	New policy										
1.0	Effective Date: 09/26/2022	UM medical management system update for MAPPO and BCNA <table border="1" data-bbox="483 699 1365 909"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>No</td> </tr> <tr> <td>BCN</td> <td>No</td> </tr> <tr> <td>MAPPO</td> <td>Yes</td> </tr> <tr> <td>BCNA</td> <td>Yes</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	No	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	No											
MAPPO	Yes											
BCNA	Yes											

\* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.

**Blue Cross Blue Shield/Blue Care Network of Michigan**  
**Medication Authorization Request Form**  
**Spevigo® (spesolimab-sbvo) HCPCS CODE: J1747**



This form is to be used by participating physicians to obtain coverage for Spevigo. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
<b>Name</b>	<b>Name</b>
<b>ID Number</b>	<b>Specialty</b>
<b>D.O.B.</b> <input type="checkbox"/> Male <input type="checkbox"/> Female	<b>Address</b>
<b>Pt weight (in kg)</b> <span style="float: right;"><b>Date recorded:</b> _____</span>	<b>City /State/Zip</b>
<b>Diagnosis</b>	<b>Phone/Fax: P: (     )     -     F: (     )     -</b>
<b>Drug Name</b> <input type="checkbox"/>	<b>NPI</b>
<b>Dose and Quantity</b>	<b>Contact Person</b>
<b>Directions</b>	<b>Contact Person Phone / Ext.</b>
<b>Date of Service(s)</b>	

**STEP 1: DISEASE STATE INFORMATION**

1. Is this request for initiation or renewal of therapy?  Initiation  Continuation  *Date patient started therapy:* \_\_\_\_\_
2. Please provide the NPI number for the place of administration: \_\_\_\_\_
3. **Initiation AND Continuation of therapy:**
  - a. Please check the patient's diagnosis:
    - History of generalized pustular psoriasis (GPP) as defined by the European Rare and Severe Psoriasis Expert Network
    - Other: \_\_\_\_\_
  - b. How is the patient experiencing a GPP flare of moderate-to-severe intensity?
    - A Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score  $\geq 3$
    - New or worsening pustules
    - GPPGA pustulation sub-score  $\geq 2$
    - $\geq 5\%$  of body surface area (BSA) with erythema and the presence of pustules
  - a. Has the patient experienced treatment failure with one of the following?
    - Acitretin
    - Cyclosporine
    - Methotrexate
    - Infliximab (For example: Inflectra, Avsola, Renflexis or Remicade)
    - Others: \_\_\_\_\_
  - b. Will the patient be receiving Spevigo with other biologic agents (for example: Infliximab, Humira, Kineret, Entyvio, or Tremfya, etc.) or with targeted DMARDs (for example: Otezla)?
    - yes  no **Comment:** \_\_\_\_\_
4. **Continuation of therapy - Please include rationale for continuation of therapy** \_\_\_\_\_

**Please add any other supporting medical information necessary for our review**

**Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.**

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

<b>Physician's Name</b>	<b>Physician Signature</b>	<b>Date</b>
<b>Step 2: Checklist</b>	<input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Attached Chart Notes	<input type="checkbox"/> Labs
<b>Step 3: Submit</b>	<b>By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979</b>	<b>By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320</b>

**Confidentiality notice:** This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.